IVVD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 3, 2023 in the Class Action Filed on Behalf of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Shareholders

NEW YORK, Feb. 7, 2023

This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.
Lead Plaintiff Deadline: April 3, 2023
No obligation or cost to you.

Learn more about your recoverable losses in IVVD:
https://www.kleinstocklaw.com/pslra-1/invivyd-class-action-submission-form?id=36279&from=4

Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. NEWS - IVVD NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Invivyd you have until April 3, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Invivyd securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.